Solid Biosciences Inc. Operating Income
Solid Biosciences Inc. (SLDB) reported Operating Income of -$57.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Solid Biosciences Inc. operating income (loss) for the quarter ending 2026-06-30 was -$57.38M.
- Solid Biosciences Inc. operating income (loss) for the quarter ending 2026-03-31 was -$57.31M.
- Solid Biosciences Inc. operating income (loss) for the quarter ending 2025-12-31 was -$49.40M.
- Solid Biosciences Inc. operating income (loss) for the quarter ending 2025-09-30 was -$48.06M.
- Solid Biosciences Inc. operating income (loss) for fiscal 2025 was -$179.21M.
- Solid Biosciences Inc. operating income (loss) for fiscal 2024 was -$129.73M.
- Solid Biosciences Inc. operating income (loss) for fiscal 2023 was -$104.25M.
- Solid Biosciences Inc. operating income (loss) for fiscal 2022 was -$106.45M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$57.38M 10-Q · filed 2026-08-06 | -$114.69M 10-Q · filed 2026-08-06 | -$164.09M derived: sum of 3 quarters · filed 2026-08-06 | -$212.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$57.31M 10-Q · filed 2026-05-12 | -$106.71M derived: sum of 2 quarters · filed 2026-05-12 | -$154.77M derived: sum of 3 quarters · filed 2026-05-12 | -$196.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$49.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$97.46M derived: sum of 2 quarters · filed 2026-03-19 | -$139.15M derived: sum of 3 quarters · filed 2026-08-06 | -$179.21M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$48.06M 10-Q · filed 2025-11-03 | -$89.75M derived: sum of 2 quarters · filed 2026-08-06 | -$129.80M 10-Q · filed 2025-11-03 | -$169.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$41.69M 10-Q · filed 2026-08-06 | -$81.75M 10-Q · filed 2026-08-06 | -$121.64M derived: sum of 3 quarters · filed 2026-08-06 | -$156.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$40.05M 10-Q · filed 2026-05-12 | -$79.95M derived: sum of 2 quarters · filed 2026-05-12 | -$115.13M derived: sum of 3 quarters · filed 2026-05-12 | -$142.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$39.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$75.08M derived: sum of 2 quarters · filed 2026-03-19 | -$102.87M derived: sum of 3 quarters · filed 2026-03-19 | -$129.73M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$35.18M 10-Q · filed 2025-11-03 | -$62.97M derived: sum of 2 quarters · filed 2025-11-03 | -$89.83M 10-Q · filed 2025-11-03 | -$112.10M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$27.79M 10-Q · filed 2025-08-12 | -$54.65M 10-Q · filed 2025-08-12 | -$76.92M derived: sum of 3 quarters · filed 2025-08-12 | -$100.03M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$26.86M 10-Q · filed 2025-05-15 | -$49.13M derived: sum of 2 quarters · filed 2025-05-15 | -$72.24M derived: sum of 3 quarters · filed 2025-05-15 | -$99.08M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$22.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$45.38M derived: sum of 2 quarters · filed 2025-03-06 | -$72.22M derived: sum of 3 quarters · filed 2025-03-06 | -$104.25M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$23.11M 10-Q · filed 2024-11-06 | -$49.96M derived: sum of 2 quarters · filed 2024-11-06 | -$81.99M 10-Q · filed 2024-11-06 | -$116.55M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$26.84M 10-Q · filed 2024-08-13 | -$58.87M 10-Q · filed 2024-08-13 | -$93.44M derived: sum of 3 quarters · filed 2024-08-13 | -$114.57M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$32.03M 10-Q · filed 2024-05-15 | -$66.60M derived: sum of 2 quarters · filed 2024-05-15 | -$87.73M derived: sum of 3 quarters · filed 2024-05-15 | -$113.11M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$34.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$55.70M derived: sum of 2 quarters · filed 2024-03-13 | -$81.08M derived: sum of 3 quarters · filed 2024-03-13 | -$106.45M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$21.13M 10-Q · filed 2023-11-08 | -$46.51M derived: sum of 2 quarters · filed 2023-11-08 | -$71.89M 10-Q · filed 2023-11-08 | -$90.54M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | -$25.38M 10-Q · filed 2023-08-14 | -$50.75M 10-Q · filed 2023-08-14 | -$69.41M derived: sum of 3 quarters · filed 2024-03-13 | -$87.44M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | -$25.37M 10-Q · filed 2023-05-11 | -$44.02M derived: sum of 2 quarters · filed 2024-03-13 | -$62.05M derived: sum of 3 quarters · filed 2024-03-13 | -$80.74M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | -$18.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$36.68M derived: sum of 2 quarters · filed 2024-03-13 | -$55.37M derived: sum of 3 quarters · filed 2024-03-13 | -$72.25M 10-K · filed 2024-03-13 |
| 2021-09-30 | -$18.03M 10-Q · filed 2022-11-10 | -$36.72M derived: sum of 2 quarters · filed 2022-11-10 | -$53.60M 10-Q · filed 2022-11-10 | -$74.95M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | -$18.68M 10-Q · filed 2022-08-11 | -$35.57M 10-Q · filed 2022-08-11 | -$56.92M derived: sum of 3 quarters · filed 2023-03-23 | -$78.14M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | -$16.89M 10-Q · filed 2022-04-27 | -$38.23M derived: sum of 2 quarters · filed 2023-03-23 | -$59.46M derived: sum of 3 quarters · filed 2023-03-23 | -$78.43M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | -$21.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$42.57M derived: sum of 2 quarters · filed 2023-03-23 | -$61.55M derived: sum of 3 quarters · filed 2023-03-23 | -$88.41M 10-K · filed 2023-03-23 |
| 2020-09-30 | -$21.23M 10-Q · filed 2021-11-03 | -$40.20M derived: sum of 2 quarters · filed 2021-11-03 | -$67.06M 10-Q · filed 2021-11-03 | -$99.39M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$18.97M 10-Q · filed 2021-08-16 | -$45.83M 10-Q · filed 2021-08-16 | -$78.16M derived: sum of 3 quarters · filed 2021-08-16 | -$107.88M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$26.86M 10-Q · filed 2021-05-14 | -$59.19M derived: sum of 2 quarters · filed 2021-05-14 | -$88.91M derived: sum of 3 quarters · filed 2021-05-14 | -$115.88M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$32.33M 10-K · filed 2020-03-12 | -$62.05M derived: sum of 2 quarters · filed 2020-11-05 | -$89.02M derived: sum of 3 quarters · filed 2020-11-05 | -$119.32M 10-K · filed 2022-03-14 |
| 2019-09-30 | -$29.72M 10-Q · filed 2020-11-05 | -$56.69M derived: sum of 2 quarters · filed 2020-11-05 | -$86.99M 10-Q · filed 2020-11-05 | -$109.37M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$26.97M 10-Q · filed 2020-08-06 | -$57.27M 10-Q · filed 2020-08-06 | -$79.66M derived: sum of 3 quarters · filed 2020-08-06 | -$98.81M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | -$30.30M 10-Q · filed 2020-05-07 | -$52.69M derived: sum of 2 quarters · filed 2020-05-07 | -$71.84M derived: sum of 3 quarters · filed 2020-05-07 | -$90.02M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$22.39M 10-K · filed 2020-03-12 | -$41.54M derived: sum of 2 quarters · filed 2020-03-12 | -$59.71M derived: sum of 3 quarters · filed 2020-03-12 | -$75.69M 10-K · filed 2021-03-15 |
| 2018-09-30 | -$19.15M 10-K · filed 2020-03-12 | -$37.33M derived: sum of 2 quarters · filed 2020-03-12 | -$53.30M 10-Q · filed 2019-11-12 | -$68.46M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$18.18M 10-K · filed 2020-03-12 | -$34.15M 10-Q · filed 2019-08-14 | -$49.31M derived: sum of 3 quarters · filed 2020-03-12 | -$63.01M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$15.97M 10-K · filed 2020-03-12 | -$31.13M derived: sum of 2 quarters · filed 2020-03-12 | -$44.83M derived: sum of 3 quarters · filed 2020-03-12 | -$56.72M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$15.16M 10-K · filed 2019-03-13 | -$28.86M derived: sum of 2 quarters · filed 2019-03-13 | -$40.74M derived: sum of 3 quarters · filed 2019-03-13 | -$54.86M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$13.70M 10-K · filed 2019-03-13 | -$25.58M derived: sum of 2 quarters · filed 2019-03-13 | -$39.70M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$11.89M 10-K · filed 2019-03-13 | -$26.00M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | -$14.11M 10-K · filed 2019-03-13 | |||
| 2016-12-31 | -$25.58M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |